UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events

Journal of translational medicine, 2013-03, Vol.11 (1), p.75-75, Article 75

2013

Volltextzugriff (PDF)

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Journal of clinical oncology, 2006-10, Vol.24 (30), p.4914-4921

2006

Volltextzugriff (PDF)

HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer

Scientific reports, 2024-05, Vol.14 (1), p.12129-14, Article 12129

2024

Volltextzugriff (PDF)

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations

JNCI : Journal of the National Cancer Institute, 2005-08, Vol.97 (16), p.1185-1194

2005

Volltextzugriff (PDF)

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer

EBioMedicine, 2015-03, Vol.2 (3), p.264-271

2015

Volltextzugriff (PDF)

The Hemochromatosis Gene Product Complexes with the Transferrin Receptor and Lowers Its Affinity for Ligand Binding

Proceedings of the National Academy of Sciences - PNAS, 1998-02, Vol.95 (4), p.1472-1477

1998

Volltextzugriff (PDF)

Hereditary Hemochromatosis: Effects of C282Y and H63D Mutations on Association with β2-microglobulin, Intracellular Processing, and Cell Surface Expression of the HFE Protein in COS-7 Cells

Proceedings of the National Academy of Sciences - PNAS, 1997-11, Vol.94 (23), p.12384-12389

1997

Volltextzugriff (PDF)

The Hemochromatosis Founder Mutation in HLA-H Disrupts β2-Microglobulin Interaction and Cell Surface Expression

The Journal of biological chemistry, 1997-05, Vol.272 (22), p.14025-14028

1997

Volltextzugriff (PDF)

Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Journal of clinical oncology, 2023-11, Vol.41 (31), p.4852-4863

2023

Volltextzugriff (PDF)

Immunohistochemistry of HLA-H, the Protein Defective in Patients with Hereditary Hemochromatosis, Reveals Unique Pattern of Expression in Gastrointestinal Tract

Proceedings of the National Academy of Sciences - PNAS, 1997-03, Vol.94 (6), p.2534-2539

1997

Volltextzugriff (PDF)

Protein Enhancement of Hammerhead Ribozyme Catalysis

Science (American Association for the Advancement of Science), 1993-10, Vol.262 (5130), p.99-102

1993

Volltextzugriff (PDF)

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

The lancet oncology, 2024-04, Vol.25 (4), p.439-454

2024

Volltextzugriff (PDF)

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Nature medicine, 2024-07, Vol.30 (7), p.1933-1942

2024

Volltextzugriff (PDF)

Influence of Human Immunodeficiency Virus Nucleocapsid Protein on Synthesis and Strand Transfer by the Reverse Transcriptase in Vitro(∗)

The Journal of biological chemistry, 1995-06, Vol.270 (25), p.15005-15011

1995

Volltextzugriff (PDF)

Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.438-438

2022

Volltextzugriff (PDF)

Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy

American journal of physiology. Renal physiology, 2014-09, Vol.307 (5), p.F560-F570

2014

Volltextzugriff (PDF)

Responsiveness to Cetuximab without Mutations in EGFR

The New England journal of medicine, 2005-07, Vol.353 (2), p.208-209

2005

Volltextzugriff (PDF)

A 1.1-Mb transcript map of the hereditary hemochromatosis locus

Genome research, 1997-05, Vol.7 (5), p.441-456

1997

Volltextzugriff (PDF)

Efficacy of Sequential Treatment with Sunitinib-Everolimus in an Orthotopic Mouse Model of Renal Cell Carcinoma

Anticancer research, 2012-07, Vol.32 (7), p.2399-2406

2012

Volltextzugriff (PDF)

Identification of a predictive biomarker for patritumab (P), an anti-HER3 monoclonal antibody, in advanced NSCLC

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e19016-e19016

2014

Volltextzugriff (PDF)

Prognostic Value of Chromogranin A and Neuron-Specific Enolase in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET): Phase III RADIANT-3 Study Results: 2011 ACG Presidential Poster: 143

The American journal of gastroenterology, 2011-10, Vol.106, p.S58

2011

Volltextzugriff (PDF)

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-mediate gastrointestinal adverse events

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.8593-8593

2012

Volltextzugriff (PDF)

Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke

Stroke (1970), 2005-11, Vol.36 (11), p.2346-2350

2005

Volltextzugriff (PDF)

Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy

Arteriosclerosis, thrombosis, and vascular biology, 2008-03, Vol.28 (3), p.562-567

2008

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(44)

Sprache

Englisch
(44)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer

The Hemochromatosis Gene Product Complexes with the Transferrin Receptor and Lowers Its Affinity for Ligand Binding

Hereditary Hemochromatosis: Effects of C282Y and H63D Mutations on Association with β2-microglobulin, Intracellular Processing, and Cell Surface Expression of the HFE Protein in COS-7 Cells

The Hemochromatosis Founder Mutation in HLA-H Disrupts β2-Microglobulin Interaction and Cell Surface Expression

Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Immunohistochemistry of HLA-H, the Protein Defective in Patients with Hereditary Hemochromatosis, Reveals Unique Pattern of Expression in Gastrointestinal Tract

Protein Enhancement of Hammerhead Ribozyme Catalysis

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Trastuzumab Deruxtecan With Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study

Influence of Human Immunodeficiency Virus Nucleocapsid Protein on Synthesis and Strand Transfer by the Reverse Transcriptase in Vitro(∗)

Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC)

Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy

Responsiveness to Cetuximab without Mutations in EGFR

A 1.1-Mb transcript map of the hereditary hemochromatosis locus

Efficacy of Sequential Treatment with Sunitinib-Everolimus in an Orthotopic Mouse Model of Renal Cell Carcinoma

Identification of a predictive biomarker for patritumab (P), an anti-HER3 monoclonal antibody, in advanced NSCLC

Prognostic Value of Chromogranin A and Neuron-Specific Enolase in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET): Phase III RADIANT-3 Study Results: 2011 ACG Presidential Poster: 143

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-mediate gastrointestinal adverse events

Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke

Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy

Suchergebnisse filtern